DMAC DiaMedica Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why DMAC matters now
DiaMedica Therapeutics Inc. (DMAC) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.67 with -0.52% on the session and $413.3M in market capitalization; recent performance reads 1-month +5.03% and YTD -26.51%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.0M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.9%.
The latest indexable market news headline is "DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Semba Charles Pauling filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.66
P/S
0.00
EV/EBITDA
-8.87
DCF Value
$0.30
FCF Yield
-9.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-77.1%
ROA
-66.1%
ROIC
-77.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.0M | $-0.19 |
| Q4 2025 | $0.00 | $-8.7M | $-0.17 |
| FY 2025 | $0.00 | $-32.8M | $-0.70 |
| Q3 2025 | $0.00 | $-8.6M | $-0.17 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.33
Target (Median)
$8.00
Target Range
$7.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.00
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.